Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with Multiple Myeloma
M-inSight is a mass spectrometry-based minimal residual disease (MS-MRD) assay offers a groundbreaking approach to monitoring Multiple Myeloma (MM) therapy. By simultaneously tracking M-proteins, therapeutic antibodies, and immunoglobulin levels in a single test, we provide a comprehensive view of treatment response and drug efficacy. This proof-of-concept study demonstrates the potential of MS-MRD to optimize patient management, particularly in refractory cases, by delivering precise insights into therapy response kinetics.